FMC CORP FMC

Healthcare SIC 2800 - Chemicals & Allied Products NAICS Manufacturing › Chemical Manufacturing derived NYSE

FMC Corporation is a global agricultural sciences company dedicated to providing farmers with innovative solutions that increase the productivity and resilience of their land. We operate in a single distinct business segment. We develop, market and sell all three major classes of crop protection chemicals (insecticides, herbicides and fungicides) as well as biologicals, crop nutrition, and seed treatment products, which we group as plant health. FMC's innovative crop protection solutions help growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC is committed to discovering new insecticide, herbicide, and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet.

Last close 12.97 2026-09-04
Market cap $1.62B 2026-06-30 share count
52-week range 9.95 - 38.68

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield17.9%
Diluted EPS-17.88

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.47B$4.25B$4.49B$5.80B$5.05B$4.64B$4.61B$4.29B$2.53B$2.27B
Cost of revenue $2.18B$2.60B$2.66B$3.48B$2.88B$2.60B$2.53B$2.41B$1.58B$1.43B
Gross profit $1.28B$1.65B$1.83B$2.33B$2.16B$2.05B$2.08B$1.88B$951.8M$842.8M
SG&A $684.9M$644.6M$734.3M$775.2M$714.1M$729.7M$792.9M$790.0M$581.7M$419.4M
Total operating expenses $5.10B$3.74B$3.93B$4.66B$4.01B$3.75B$3.79B———
Operating income -$1.63B$506.5M$555.6M$1.14B$1.03B$896.9M$821.6M$740.9M$158.5M$197.8M
Interest expense $239.6M$235.8M$237.2M$151.8M$131.1M$151.3M$160.4M$134.5M$80.0M$63.5M
Pre-tax income -$1.89B$252.5M$300.2M$983.9M$897.8M$731.0M$655.0M$608.4M$95.8M$111.6M
Income tax $314.2M$150.9M$1.12B$145.2M$92.5M$151.2M$111.5M$70.8M$228.9M$38.2M
Net income -$2.24B$341.1M$1.32B$736.5M$739.6M$552.4M$477.4M$502.1M$535.8M$209.1M
EPS, basic -17.882.7310.555.835.764.263.643.723.991.56
EPS, diluted -17.882.7210.535.815.734.233.623.693.991.56
Shares, diluted (wtd. avg.) 125.2M125.4M125.5M126.7M129.1M130.6M132.0M135.9M134.3M134.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $584.5M$357.3M$302.4M$572.0M$516.8M$568.9M$339.1M$134.4M$281.8M$60.2M
Receivables $2.06B$2.90B$2.70B$2.87B$2.58B$2.33B$2.23B$2.14B$1.92B$1.69B
Inventory $1.22B$1.20B$1.72B$1.65B$1.52B$1.10B$1.02B$1.03B$942.8M$478.9M
Total current assets $4.96B$4.96B$5.13B$5.44B$5.05B$4.38B$4.07B$4.03B$3.65B$2.85B
Property, plant and equipment $707.4M$849.7M$892.5M$849.6M$817.0M$771.7M$758.0M$756.9M$808.9M$538.1M
Goodwill $0$1.51B$1.59B$1.59B$1.46B$1.47B$1.47B$1.47B$1.20B$498.7M
Other intangibles $2.36B$2.36B$2.47B$2.51B$2.52B$2.63B$2.63B$2.70B$2.63B$719.9M
Total assets $9.69B$11.65B$11.93B$11.17B$10.67B$10.19B$9.87B$9.97B$9.21B$6.14B
Accounts payable $771.0M$768.5M$602.4M$1.25B$1.14B$946.7M$900.1M$795.5M$654.4M$317.4M
Short-term debt $585.6M$76.1M$96.5M$88.5M$84.5M$93.6M$82.8M$386.0M$101.2M$2.4M
Total current liabilities $3.76B$3.02B$3.38B$3.80B$3.52B$2.83B$2.72B$2.99B$2.21B$1.44B
Long-term debt $2.77B$3.03B$3.02B$2.73B$2.73B$2.93B$3.03B$2.15B$2.99B$1.80B
Retained earnings $4.17B$6.64B$6.59B$5.56B$5.09B$4.51B$4.19B$4.33B$3.95B$3.51B
Total equity $2.07B$4.49B$4.43B$3.40B$3.14B$3.08B$2.67B$3.21B$2.71B$1.99B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$6.2M$736.7M-$300.3M$660.0M$898.6M$736.8M$555.6M$362.7M$232.0M$313.9M
Depreciation and amortisation $173.6M$176.3M$184.3M$169.4M$170.9M$162.7M$150.1M$150.2M$97.8M$85.8M
Stock-based compensation $24.0M$23.8M$25.9M$24.2M$17.8M$18.9M$25.6M$22.5M$21.1M$20.2M
Capital expenditure $96.3M$67.9M$133.9M$142.3M$100.1M$67.2M$93.9M$83.0M$38.3M$66.8M
Investing cash flow -$99.7M$263.6M-$154.4M-$266.4M-$131.7M-$200.4M-$195.9M-$37.5M-$1.29B-$70.6M
Financing cash flow $386.0M-$870.1M$331.5M-$237.4M-$747.9M-$250.3M-$87.0M-$397.3M$1.21B-$366.3M
Dividends paid $291.3M$290.6M$290.5M$267.5M$247.2M$228.5M$210.3M$89.2M$88.8M$88.6M
Buybacks $0$0$75.0M$100.0M$400.0M$50.0M$400.0M$200.0M$0$11.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000037785-26-000041.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Interest expense
  • R&D
  • Receivables
Interest expense, R&D, Receivables by fiscal year, in US dollars The same figures are in the table below this chart. 0 1B 2B 3B Interest expense, FY2016: 63.5M Receivables, FY2016: 1.7B Interest expense, FY2017: 80M Receivables, FY2017: 1.9B Interest expense, FY2018: 134.5M Receivables, FY2018: 2.1B Interest expense, FY2019: 160.4M Receivables, FY2019: 2.2B Interest expense, FY2020: 151.3M Receivables, FY2020: 2.3B Interest expense, FY2021: 131.1M Receivables, FY2021: 2.6B Interest expense, FY2022: 151.8M Receivables, FY2022: 2.9B Interest expense, FY2023: 237.2M Receivables, FY2023: 2.7B Interest expense, FY2024: 235.8M Receivables, FY2024: 2.9B Interest expense, FY2025: 239.6M Receivables, FY2025: 2.1B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Interest expense $63.5M $80.0M $134.5M $160.4M $151.3M $131.1M $151.8M $237.2M $235.8M $239.6M
R&D — — — — — — — — — —
Receivables $1.69B $1.92B $2.14B $2.23B $2.33B $2.58B $2.87B $2.70B $2.90B $2.06B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • Material agreement signed Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2800

TickerCompanyMarket capP/ERevenue growth
SOLS Solstice Advanced Materials Inc. $10.12B 42.8x 3.1%
PRM Perimeter Solutions, Inc. $5.20B — 16.4%
NGVT Ingevity Corp $2.43B — -2.7%
IOSP INNOSPEC INC. $2.31B 20.1x -3.7%
CC Chemours Co $2.30B — 0.4%
OLN OLIN Corp $1.98B — 3.7%
HUN Huntsman CORP $1.69B — -5.8%
ECVT Ecovyst Inc. $1.12B — 20.9%